Monte Rosa Therapeutics (GLUE) Accumulated Expenses (2020 - 2026)

Monte Rosa Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $25.6 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 57.14% year-over-year to $25.6 million in Q1 2026; TTM through Mar 2026 was $25.6 million, a 57.14% increase from a year earlier, with the FY2025 full-year figure at $26.7 million, up 42.1% from the prior year.
• Accumulated Expenses fell to $25.6 million in Q1 2026 per GLUE's latest filing, from $26.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $26.7 million in Q4 2025 and bottomed at $3.2 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $9.0 million (2022), against an average of $11.8 million.
• Across the five-year window, Accumulated Expenses sank 53.73% in 2024 and jumped 360.21% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $14.6 million in 2022, then slumped by 47.92% to $7.6 million in 2023, then surged by 147.4% to $18.8 million in 2024, then jumped by 42.1% to $26.7 million in 2025, then retreated by 4.12% to $25.6 million in 2026.
• Per Business Quant, the three latest GLUE Accumulated Expenses figures stand at $25.6 million (Q1 2026), $26.7 million (Q4 2025), and $17.9 million (Q3 2025).